Vaccines: Poised To Deliver Significant Growth in Emerging Markets

Transcription

1 Vaccines: Poised To Deliver Significant Growth in Emerging Markets 4 th DVFA Symposium Life Science Pierre Morgon Vice-President, Franchise & Global Marketing Operations, Sanofi Pasteur Frankfurt, May 17, 2011

2 Forward Looking Statements 2 This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words expects, anticipates, believes, intends, estimates, plans and similar expressions. Although sanofi-aventis management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofiaventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group s ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under Risk Factors and Cautionary Statement Regarding Forward-Looking Statements in sanofi-aventis annual report on Form 20-F for the year ended December 31, Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

3 Agenda 3 Emerging Markets and Vaccines: Two Growth Platforms for Sanofi Sanofi Pasteur: a Global Leader in Vaccines Committed to Public Health Sanofi Pasteur: Capturing Growth Opportunities in Emerging Markets

4 Developing Sustainable Growth Platforms 4 Emerging Markets Diabetes Solutions Human Vaccines Rare Diseases Consumer Health Care Innovative Products Animal Health

5 Expanding our Unparalleled Leadership Position in Emerging Markets 5 In 2010 Emerging Markets (1) sales 9.1bn, +16.3% (2) 30% of consolidated sales Pharmacy in Brazil (1) World less North America, Western Europe, Japan and Australia/New Zealand (2) Growth at constant exchange rates.

6 : a Global Leader in Vaccines Committed to Public Health 6 In 2010 More than 1 billion doses of vaccines to immunize more than 500m people throughout the world Vaccines consolidated sales 3.8bn, +4.8% (1) (1) Growth at constant exchange rates

7 Agenda 7 Emerging Markets and Vaccines: Two Growth Platforms for Sanofi Sanofi Pasteur: a Global Leader in Vaccines Committed to Public Health Sanofi Pasteur: Capturing Growth Opportunities in Emerging Markets

8 Vaccines Strategic Segment of Health Care 8 Most cost-effective health-care intervention available Largest birth cohorts in emerging markets (1) High degree of innovation and limited exposure to generics Improved pricing due to significant health benefits Significant unmet demand in emerging markets U.S.: 4.2m Mexico: 2.2m Brazil: 3.7m Western EU: 4.0m Russia: 1.6m China: 18.7m India: 25.1m One of the fastest growing markets (1) Estimated birth cohorts in millions, Census Bureau, updated November 26, 2009

9 Sanofi A Unique Position in Vaccines 9 A strong heritage A broad and diversified product offering A success story based on leadership and innovation Leadership in Influenza, Meningitis and Pediatric vaccines New wave of innovation in preparation with vaccines against Dengue Fever and Clostridium Difficile A Global Leader in Vaccines FY2010 sales: 3,808m, +4.8% (1) JV with Merck in EU: 918m (2) 22% market share in 2010 (3) Diversified and Balanced Portfolio Pandemic Influenza 12% Seasonal Influenza 22% Other Travel & 4% Endemics 10% FY2010 Sales % by Franchise Boosters 12% Polio/ Pertussis/ Hib 26% Meningitis/ Pneumonia 14% (1) Growth at constant exchange rates (2) Accounted for using the equity method (3) Based on reported FY2010 results and Sanofi Pasteur internal estimates for Others Sanofi Pasteur MS estimate includes 50% of Sanofi Pasteur MSD sales, excluding pandemic sales

10 Sanofi Pasteur Good Start to the Year Q Sales: 602m, +9.6% at CER excluding A/H1N1 (1) Strong Emerging Markets sales of 282m, +37.1% at CER excluding A/H1N1, driven by: Record seasonal flu campaign Solid growth of Good performance of and in the U.S. FDA approval granted for for infants and toddlers Vaccines Consolidated Sales ( m) A/H1N1 413m Q Q Polio/Pertussis/Hib Meningitis/Pneumonia Travel & Endemics Pandemic Influenza 602m Seasonal Influenza Boosters Other (1) Q sales decreased by -38.3% at constant exchange rates when including 413m of A/H1N1 vaccine sales in Q1 2010

11 Historical Performance Driven by the U.S. and Europe - Still Room to Grow 11 Highly concentrated market 4 large international players High immunization rates Opportunities remain in all age segments Differentiation as competitive advantage Further growth to come from life cycle management and innovative vaccines 100% 80% 60% 40% 20% U.S.: Market Leader Everywhere We Compete Market Share by Major Franchise YTD December 2010 (1) 32% 32% 68% 68% 49% 51% 95% 0% Pediatric Pertussis (2) Boosters Flu Meningitis Sanofi Pasteur All other competitors (1) 2010 Competitors annual earnings statements and Sanofi Pasteur internal sales data (2) Seasonal influenza - Internal projections based on published CDC and manufacturer statements

12 Significant Future Growth to Be Fuelled by The Emerging Markets 12 Large population and birth cohorts Low immunization rates Economic growth driving middle class and private sector expansion Expansion of government healthcare coverage Many unmet medical needs Projected Emerging Market (1) Vaccines Sales (2) ( bn) CAGR 15% e 2015e (1) Emerging markets includes Asia-Pacific (excluding Japan, Australia and New Zealand), Africa, Middle-East, Eastern Europe and Latin America (2) Sanofi Pasteur internal estimates excluding pandemic influenza sales

13 Agenda 13 Emerging Markets and Vaccines: Two Growth Platforms for Sanofi Sanofi Pasteur: a Global Leader in Vaccines Committed to Public Health Sanofi Pasteur: Capturing Growth Opportunities in Emerging Markets

14 Sanofi Pasteur Has a Well Established Presence in Emerging Markets 14 FY 2010 Sanofi Pasteur sales in Emerging Markets Ranks #1 1,386m (1), +46.2% 1,025m, +15.4%, excluding Pandemic Influenza Eastern Europe (2) Sales in 2010 (1) : 166m, +33% Latin America Sales in 2010 (1) : 601m, + 116% Africa & Middle East Sales in 2010 (1) : 226m, +16% Asia Sales in 2010 (1) : 342m, + 21% Sales growth is at constant exchange rates (1) Including pandemic vaccine sales (2) Includes Turkey

15 Ensuring Long-Term Growth Through Tailored R&D, Industrial and Commercial Footprint 15 Present in over 100 countries Investing in local manufacturing 4 international sites: China, Thailand, Argentina and India 2 sites under construction: China and Mexico Regional approaches for R&D project execution 2 main centers: China and India Emerging Markets Industrial and R&D Presence Beijing Ocoyoacac Shenzhen Shantha a strategic asset Cost-effective manufacturing base GPO Thailand Offering adapted to UNICEF/GAVI segment Pilar Shantha R&D pipeline (Rotavirus, HPV) Industrial site R&D site

16 A Strong Record of Alliances To Access Emerging Markets 16 Partner of choice Over 14 partnerships Selected Sanofi Pasteur Partnerships in Emerging Markets MEFAR Chumakov Built long-standing relationships New partnerships in development Birmex Butantan The Biovac Institute EPI

17 A Solid R&D Pipeline to Fuel our Growth 17 Phase I Tuberculosis Recombinant subunit vaccine Phase II ACAM-Cdiff Clostridium difficile Toxoid vaccine Phase III Dengue Mild-to-severe dengue fever vaccine Streptococcus pneumonia Meningitis & pneumonia vaccine Rabies mab post exposure prophylaxis Hexaxim DTP-HepB-Polio-Hib vaccine Pseudomonas aeruginosa Antibody fragment product Prevention of ventilator-associated pneumonia Rotavirus Live Attenuated Tetravalent Rotavirus oral vaccine Rabies VRVg Purified vero rabies vaccine Meninge ACYW conj. 2 nd generation meningococcal conjugate Infant vaccine Quadracel Diphtheria, tetanus, pertussis and polio vaccine; 4-6 years of age Fluzone QIV Quadrivalent inactivated influenza vaccine Primary Target Market DTP-HepB-Polio-Hib Pediatric hexavalent vaccine Developed Emerging Developed & Emerging

18 A Broad Product Offering Well Suited for Emerging Markets Sanofi Pasteur Sales Performance in Emerging Markets (1) Sesaonal Influenza 257m, +10.9% Polio/Pertussis/Hib 384m, +11.4% Shanchol Others 15m Travel & other endemics 235m, +15.8% Meningitis/ Pneumo 101m, +25.6% Boosters 33m, +32% Pandemic Influenza 361m (1) Sales growth at constant exchange rates

19 A Pediatric Combo Portfolio Tailored to Emerging Markets 19 3 combo families to address different market cluster needs 5-component acellular Pertussis 2-component acellular Pertussis Hexaxim First launches expected end of 2013 Whole cell Pertussis Unmatched capacity for Oral and Inactivated Polio Vaccines Pediatric combination includes Diphtheria, Tetanus, Pertussis, inactivated Polio, plus Haemophilus b and/or Hepatitis B depending on vaccine

20 The Broadest Seasonal Influenza Vaccines Offering of the Industry 20 Seasonal Influenza Vaccines Unique Manufacturing Platform Swiftwater Shenzhen Northern Hemisphere: ~40% MS (1) Southern Hemisphere: ~70% MS (1) 2010 net sales of 257m in Emerging Markets Val de Reuil New differentiated offering Ocoyoacac First intradermal influenza vaccine Existing sites Under Construction (1) Market shares (MS) based on reported FY2010 results and Sanofi Pasteur internal estimates for other companies (includes all countries in a given hemisphere)

21 Dengue: A Growing Health Concern 21 Mosquito-borne disease Global Prevalence of Dengue (1) 2 nd most widespread tropical disease after Malaria 2.5bn people in tropical and subtropical region; annual incidence of m cases Increasing geographic spread and burden of disease High economic burden in endemic countries No effective drug treatments No effective prevention Areas infested with Aedes aegypti Areas with Aedes aegypti and dengue epidemic activity (1) Sources: WHO

22 Developing a Safe and Effective Tetravalent Vaccine against Dengue 22 Chimerivax TM technology Phase III study on-going Over 15 countries involved Dengue Facilities Construction Status (Neuville, France) Around 39,000 subjects recruited including around 11,000 children Expected to be first to market Market estimated to be over 1 billion First submissions planned in 2013 Partnering Dengue Vaccine Initiative (DVI) 100m dose capacity To be online end 2013

23 Sanofi pasteur in Asia 23 China Sales of 104m in 2010 (1) Leadership position in flu Shenzhen plant construction and validation finalized Growth driven by both pediatric and adult vaccines Continuing history of first-to-market (Flu, Hib, Pneumo, and IPV) Launch of in May 2011 India Sales contributing to Polio eradication of 48m in 2010 (1) Broad portfolio adapted to market Complementary Sanofi Pasteur/ Shantha vaccines range Strong presence in pediatric vaccines with Expanded presence and coverage OPV vaccine supplier IPV: Inactivated Polio vaccine (1) Including pandemic vaccine sales OPV: Oral Polio vaccine

24 in Latin America 24 Brazil Sales of 294m in 2010 (1) Flu leadership position Delivered Yellow Fever for outbreak control Introduction of new vaccines Preparing Dengue vaccine introduction into public sector Mexico Sales of 185m in 2010 (1) Flu leadership position Local production platform in construction Pediatric combo vaccine leadership Growth driven by introduction of new vaccines in the public market (1) Including pandemic vaccine sales

25 Ensuring Long-term Growth in Emerging Markets 25 Broad vaccines offering adapted to local needs Strong industrial and commercial presence Key local partnerships Regional base Promising projects in development